VIALE, GIULIA
 Distribuzione geografica
Continente #
AS - Asia 235
NA - Nord America 182
EU - Europa 141
SA - Sud America 35
Totale 593
Nazione #
US - Stati Uniti d'America 173
SG - Singapore 123
IT - Italia 76
CN - Cina 61
BR - Brasile 32
HK - Hong Kong 27
DE - Germania 21
VN - Vietnam 11
GB - Regno Unito 9
FI - Finlandia 7
FR - Francia 6
NL - Olanda 6
CA - Canada 5
AT - Austria 4
IN - India 4
ES - Italia 3
JP - Giappone 3
MX - Messico 3
PL - Polonia 3
RU - Federazione Russa 3
KG - Kirghizistan 2
UA - Ucraina 2
AE - Emirati Arabi Uniti 1
CO - Colombia 1
CR - Costa Rica 1
ID - Indonesia 1
LK - Sri Lanka 1
SE - Svezia 1
SR - Suriname 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 593
Città #
Singapore 75
Ashburn 30
Hong Kong 27
Dallas 22
Milan 17
San Jose 17
Shanghai 13
Beijing 11
Boardman 11
Hefei 9
New York 9
Nuremberg 9
Orem 8
Los Angeles 7
Ho Chi Minh City 6
Rome 6
Chicago 4
Denver 4
Hanoi 4
London 4
São Paulo 4
Cesano Boscone 3
Chennai 3
Cornaredo 3
Costa de' Nobili 3
Helsinki 3
Lauterbourg 3
Mexico City 3
Montreal 3
Naples 3
Phoenix 3
St Louis 3
Tokyo 3
Bari 2
Bishkek 2
Brooklyn 2
Buffalo 2
Cagliari 2
Falkenstein 2
Frankfurt am Main 2
Fucecchio 2
Jequié 2
Lappeenranta 2
Livorno 2
Moscow 2
Pisa 2
Poplar 2
Porto Alegre 2
Verona 2
Warsaw 2
Wolfhagen 2
Amsterdam 1
Andradas 1
Annapolis 1
Araguaína 1
Atlanta 1
Bandaragama 1
Bekasi 1
Biên Hòa 1
Bologna 1
Brasília 1
Cabo Frio 1
Caicó 1
Calgary 1
Cartagena 1
Catania 1
Caxias do Sul 1
Charleston 1
City of London 1
Curitiba 1
Dachne 1
Dnipro 1
Garanhuns 1
Guangzhou 1
Guarapari 1
Hangzhou 1
Honolulu 1
Houston 1
Itanhaém 1
Lawrence 1
Lorain 1
Manchester 1
Maricá 1
Messina 1
Nova Friburgo 1
Padua 1
Palestrina 1
Paramaribo 1
Paris 1
Parnaíba 1
Pasadena 1
Perdões 1
Perris 1
Pirapora do Bom Jesus 1
Pittsburgh 1
Ponta Grossa 1
Presidente Prudente 1
Princeton 1
Puerto Cabello 1
Quanzhou 1
Totale 418
Nome #
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice 113
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy 64
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response 62
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer 59
Completion Rate and Positive Results Reporting among Immunotherapy Trials in Breast Cancer, 2004-2023 53
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 48
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial 44
Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak 39
Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions 37
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 10
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer 10
From intrinsic to adaptive clusters in breast cancer 9
HER2-Low breast cancer: Pathological and clinical landscape 9
Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology 9
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies 8
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies 8
Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients with Cancer: A Review 7
Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer 7
Profile of buparlisib and its potential in the treatment of breast cancer: Evidence to date 7
Recent advances in triple negative breast cancer: The immunotherapy era 7
Opportunities and challenges of implementing Pharmacogenomics in cancer drug development 7
Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer 6
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer 5
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 5
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review 3
Trastuzumab Biosimilars Setting the Pace for the Provision of a Cost Effective Oncological Care: Regulatory and Clinical Issues 1
Totale 637
Categoria #
all - tutte 2.971
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.971


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20232 2 0 0 0 0 0 0 0 0 0 0 0
2023/202419 0 0 0 0 0 0 0 0 0 0 8 11
2024/2025207 29 11 3 14 19 29 28 30 14 8 8 14
2025/2026408 37 44 21 70 87 118 31 0 0 0 0 0
Totale 637